MORGANTOWN, W.Va. (AP) — The Blanchette Rockefeller Neurosciences Institute says its research into Alzheimer's and other neurological diseases will move into human clinical trials in the next few years.
The institute at West Virginia University announced Wednesday it has a new agreement with Florida-based Neurotrope BioScience to investigate promising new diagnostic techniques and therapeutic drugs.
It hopes to introduce a non-invasive diagnostic test in 2014 then move into drug testing by 2018.
Dr. Daniel Alkon is scientific director at the institute. He says the drugs could be used not only for Alzheimer's, but also stroke and Fragile X Syndrome.
Neurotrope President Dr. Jim New praises the institute for ignoring conventional wisdom and quietly pursuing independent research with a fresh perspective for the last 13 years.
More than 5.4 million Americans are living with Alzheimer's.